| Literature DB >> 21206895 |
Rafael Augusto Castro Santiago Brandão1, Moises Heleno Vieira Braga, Atos Alves de Souza, Baltazar Leão Reis, Franklin Bernardes Faraj de Lima.
Abstract
BACKGROUND: Pituicytomas originate from pituicytes, modified glial cells derived from ependymal lineage that are found in the stalk and posterior lobe of pituitary gland. The clinical presentation is similar to other pituitary tumors and imaging exams may suggest pituitary adenoma. The diagnostic is based on histopathological analysis. Surgical treatment can be performed by transsphenoidal approach with good results. The prognostic is good after total tumor resection. CASE DESCRIPTION: We describe here the case of a 17-year-old patient with a history of persistent headache and visual disturbances. Magnetic resonance imaging demonstrated an enhancing solid sellar mass suggestive of pituitary adenoma. The intrasellar mass was resected through a transsphenoidal approach and the diagnosis of pituicytoma was made after histopathological analysis.Entities:
Keywords: Glioma; hypophysis; neurohypophyseal tumor; pituicytes; pituicytoma; pituitary gland; pituitary tumors
Year: 2010 PMID: 21206895 PMCID: PMC3011110 DOI: 10.4103/2152-7806.73802
Source DB: PubMed Journal: Surg Neurol Int ISSN: 2152-7806
Summary of the reported 31 cases of pituicytoma
| Patient no. | Series (ref. no.) | Age (year)/sex | Presentation | Imaging | Resection | Follow up | Recurrence/complications | Radiation therapy |
|---|---|---|---|---|---|---|---|---|
| 1 | Hurley | 26/F | Decreased visual acuity and hemianopsia | 2-cm enhancing sellar mass, T1-isointense, T2- hyperintense | TSP/STR | 3 year | None/transient Deficit | 5040 cGy |
| 2 | Brat | 55/F | Visual deficit | Suprasellar, enhancing | GTR | 1 year | None | None |
| 3 | Brat | 30/M | Headache | Suprasellar, enhancing | GTR | 1 year | None | None |
| 4 | Brat | 39/M | Headache | Solid and cystic, intrasellar, enhancing | TSP/GTR | 2 year | None | None |
| 5 | Brat | 42/M | Hypopituitarism/hemianopsia | Intrasellar, enlarged over 2 years of observation | TSP/STR | 2.5 year | 2 year progression with resection | None |
| 6 | Brat | 42/M | Visual deficit/decreased libido | Solid, suprasellar enhancing | STRl | 1 year | Re-resection for recurrence × 2 at 5 and 15 months | None |
| 7 | Brat | 46/M | Hypopituitarism | Solid, suprasellar enhancing | GTR | 8 year | None | None |
| 8 | Brat | 83/F | Visual deficit | Suprasellar | GTR | 2 year | None | None |
| 9 | Brat | 48/M | Hypogonadism | 2-cm solid, suprasellar mass encasing vessels | Craniotomy/STR | 8 months | Recurrence at 5 months with subtotal re-resection | None |
| 10 | Brat | 51/F | Visual deficit | Solid, enhancing sellar mass consistent with adenoma | GTR | Unknown | None | |
| 11 | Schultz | 66/M | Decreased visual acuity, visual field deficit | 2-cm enhancing, T1- isointense, T2-hyperintense | TSP/GTR | 2 year | None | None |
| 12 | Cenacchi | 79/F | Hypopituitarism/visual disturbances | Unknown | TSP/GTR | 6 months | None | None |
| 13 | Figarella- Branger | 59/M | Hypopituitarism | Solid, enhancing | TSP/STR | 11 year | None | None |
| 14 | Figarella- Branger | 46/M | Decreased libido/hypogonadism | Solid, enhancing, suprasellar | GTR | 4 year | None/transient hemiparesis | None |
| 15 | Figarella- Branger | 58/M | Hypopituitarism/memory deficits | Solid, enhancing, mimicking posterior clinoid meningioma | GTR | 2 year | None/DI | None |
| 16 | Uesaka | 34/M | Decreased visual acuity | Solid, enhancing, T1- isointense, T2-hyperintense | TSP/STR | 3 months | None | None |
| 17 | Katsuta | 32/F | Amenorrhea/visual field defect | Intrasellar, isointense T1 and T2, enhancing | TSP/GTR | 2 year | None/DI | None |
| 18 | Ulm | 45/M | Decreased libido/low testosterone | 2-cm solid, enhancing, suprasellar | Craniotomy/STR | Unknown | None | Stereotactic radiation |
| 19 | Kowalski | 52/M | Panhypopituitarism | Solid, heterogeneously enhancing sellar/suprasellar mass | TSP/STR | 11 months | Recurrence | Fractionated radiation after recurrence |
| 20 | Shah | 32/F | Amenorrhea/headache | Heterogeneously enhancing posterior pituitary mass, T1- isointense, T2-hyperintense | TSP/STR | 5 year | Recurrence with re-resection TSP | None |
| 21 | Shah | 45/F | Headache | Enhancing sellar/ suprasellar mass, T1- isointense, T2-hypointense | TSP | Unknown | Unknown | Unknown |
| 22 | Chen, 2005 ( | 54/M | Headache | Enhancing sellar/suprasellar mass | TSP/STR | 16 months | None | None |
| 23 | Takei | 54/F | Incidental at autopsy | None | None | None | None | None |
| 24 | Nakasu | 42/F | Amenorrhea | Homogeneously enhancing sellar/suprasellar mass | Craniotomy/STR | 5 year | None | None |
| 25 | Nakasu | 62/F | Headache/fatigue | Homogeneously enhancing sellar/suprasellar mass | Craniotomy/STR | 1.5 year | None/transient DI/hypopituitarism | None |
| 26 | Benveniste | 47/M | Hemorrhage/low LH/FSH | Hemorrhagic suprasellar mass with IVH | Craniotomy/STR | None | Unknown | None |
| 27 | Gibbs | 64/M | Bitemporal hemianopsia | Homogeneously enhancing 3-cm suprasellar mass, T1- isointense, T2-hyperintense, angiogram hypervascular capillary blush from ICA only | Cranio-orbitozygomatic craniotomy/GTR, very vascular | Unknown | Unknown | Unknown |
| 28 | Thiryayi at al, 2007 ( | 77/M | Hypogonadism Quadrantonopia bitemporal inferiorSuprasselar level | TSP/ STR | TSP/ STR | None | None | None |
| 29 | Wolfe | 71/F | Decreased visual acuity and visual field defects | Solid, enhancing mass | TSP/STR | 1.5 year | None | None |
| 30 | Orrego J. T. 2009( | 55/M | Decreased libido Dysfunction erectic ginecomastia | Suprasella mass isointense on T1 | TSP/STR | None | None | None |
| 31 | Brandao and Braga | 17/M | Headache visual Disturbance | Contrast-enhance solid sellar | TSP/STR | 24 months | None | None |
TSP: Transphenoidal Approach, STR: subtotal resection, GTR: gross-total resection
Figure 1Preoperative MRI.
Figure 2(A) Microscopic view showing a fusocellular tumor consisting of pleomorphic cells with a fascicular growth pattern. (B) Cells with eosinophilic citoplasm and clearly visible nucleoli. (C) Immunohistochemical reaction with S-100 protein.
Antibodies tested in immunohistochemical study
| Antibodies | Clone | Results |
|---|---|---|
| Proliferation antigen Ki-67 | MIB-1 | Positive |
| Epithelial membrane antigen – EMA | E29 | Negative |
| Cytokeratins of 40, 48, 50, and 50.6 kDa | AE1/AE3 | Negative |
| Protein S-100 | Policlonal | Positive |
| Glial fibrillary acidic protein – GFAP | Policlonal | Negative |
| Synaptophysin | Sy38 AFP | Negative |
| CD68 – lysosomal protein | KP1 | Negative |
| Nerve growth factor receptor | NGFR5 | Negative |
| Melanoma | PNL2 | Negative |
| Melanoma-associated gp100 antigen | HMB-45 | Negative |
| Melanoma antigen recognized by T cells – Melan A/MART-1 | A103 | Negative |